Lung-protective ventilation (reduced tidal volume and limited plateau pressure) may lead to CO2 retention. Data about the impact of hypercapnia in patients with ARDS are scarce and conflicting.
METHODS:
We performed a non-interventional cohort study with subjects with ARDS admitted from 2006 to 2021 and with PaO2/FIO2 ≤ 150 mm Hg. We examined the association between severe hypercapnia (PaCO2 ≥ 50 mm Hg) on the first 5 days after the diagnosis of ARDS and death in ICU for 930 subjects. All the subjects received lung-protective ventilation.
RESULTS:
Severe hypercapnia was noted in 552 subjects (59%) on the first day of ARDS (day 1); 323/930 (34.7%) died in the ICU. Severe hypercapnia on day 1 was associated with mortality in the unadjusted (odds ratio 1.54, 95% CI 1.16–1.63; P = .003) and adjusted (odds ratio 1.47, 95% CI 1.08–2.43; P = .004) models. In the Bayesian analysis, the posterior probability that severe hypercapnia was associated with ICU death was > 90% in 4 different priors, including a septic prior for this association. Sustained severe hypercapnia on day 5, defined as severe hypercapnia present from day 1 to day 5, was noted in 93 subjects (12%). After propensity score matching, severe hypercapnia on day 5 remained associated with ICU mortality (odds ratio 1.73, 95% CI 1.02–2.97; P = .047).
CONCLUSIONS:
Severe hypercapnia was associated with mortality in subjects with ARDS who received lung-protective ventilation. Our results deserve further evaluation of the strategies and treatments that aim to control CO2 retention.
AmatoMB, BarbasCS, MedeirosDM, MagaldiRB, SchettinoGP, Lorenzi-FilhoG, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med, 1998; 338(6):347–354.
2.
BarnesT, ZochiosV, ParharK. Re-examining permissive hypercapnia in ARDS: a narrative review. Chest, 2018; 154(1):185–195.
3.
HicklingKG, WalshJ, HendersonS, JacksonR. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med, 1994; 22(10):1568–1578.
4.
LaffeyJG, KavanaghBP. Carbon dioxide and the critically ill–too little of a good thing?. Lancet, 1999; 354(9186):1283–1286.
5.
MastersonC, OtulakowskiG, KavanaghBP. Hypercapnia: clinical relevance and mechanisms of action. Curr Opin Crit Care, 2015; 21(1):7–12.
6.
RepesséX, Vieillard-BaronA. Hypercapnia during acute respiratory distress syndrome: the tree that hides the forest!. J Thorac Dis, 2017; 9(6):1420–1425.
7.
TiruvoipatiR, GuptaS, PilcherD, BaileyM. Management of hypercapnia in critically ill mechanically ventilated patients—a narrative review of literature. J Intensive Care Soc, 2020; 21(4):327–333.
8.
O' CroininD, Ni ChonghaileM, HigginsB, LaffeyJG. Bench-to-bedside review: permissive hypercapnia. Crit Care, 2005; 9(1):51–59.
9.
Morales-QuinterosL, Camprubí-RimblasM, BringuéJ, BosLD, SchultzMJ, ArtigasA. The role of hypercapnia in acute respiratory failure. Intensive Care Med Exp, 2019; 7(Suppl 1):39.
10.
MarhongJ, FanE. Carbon dioxide in the critically ill: too much or too little of a good thing?. Respir Care, 2014; 59(10):1597–1605.
11.
FitzgeraldM, MillarJ, BlackwoodB, DaviesA, BrettSJ, McAuleyDF, McNameeJJ. Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care, 2014; 18(3):222.
12.
CombesA, FanelliV, PhamT, RanieriVM. European Society of Intensive Care Medicine Trials Group and the “Strategy of Ultra-Protective lung ventilation with Extracorporeal CO2 Removal for New-Onset moderate to severe ARDS” (SUPERNOVA) investigators. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med, 2019; 45(5):592–600.
13.
BeinT, Weber-CarstensS, GoldmannA, MüllerT, StaudingerT, BrederlauJ, et al. Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med, 2013; 39(5):847–856.
14.
KregenowDA, RubenfeldGD, HudsonLD, SwensonER. Hypercapnic acidosis and mortality in acute lung injury. Crit Care Med, 2006; 34(1):1–7.
15.
NinN, MurielA, PeñuelasO, BrochardL, LorenteJA, FergusonND, et al. VENTILA Group. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. Intensive Care Med, 2017; 43(2):200–208.
16.
MadottoF, RezoagliE, McNicholasBA, PhamT, SlutskyAS, BellaniG, LaffeyJG. LUNG SAFE Investigators and the ESICM Trials Group. Patterns and impact of arterial CO2 management in patients with acute respiratory distress syndrome: insights from the LUNG SAFE study. Chest, 2020; 158(5):1967–1982.
17.
GendreauS, GeriG, PhamT, Vieillard-BaronA, DessapMA. The role of acute hypercapnia on mortality and short-term physiology in patients mechanically ventilated for ARDS: a systematic review and meta-analysis. Intensive Care Med, 2022; 48(5):517–534.
18.
FortunaP, RodeiaS, MoraisR. What about permissive acidosis?. Intensive Care Med, 2022; 48(6):785–786.
19.
GuerinC, ReignierJ, RichardJ-C, BeuretP, GacouinA, BoulainT, et al. PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med, 2013; 368(23):2159–2168.
20.
PapazianL, ForelJ-M, GacouinA, Penot-RagonC, PerrinG, LoundouA, et al. ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med, 2010; 363(12):1107–1116.
21.
MaioloG, CollinoF, VasquesF, RapettiF, TonettiT, RomittiF, et al. Reclassifying acute respiratory distress syndrome. Am J Respir Crit Care Med, 2018; 197(12):1586–1595.
22.
ARDS Definition Task Force; RanieriVM, RubenfeldGD, ThompsonBT, FergusonND, CaldwellE, FanE, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA, 2012; 307(23):2526–2533.
23.
Acute Respiratory Distress Syndrome Network; BrowerRG, MatthayMA, MorrisA, SchoenfeldD, ThompsonBT, WheelerA. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med, 2000; 342:1301–1308.
24.
Le GallJR, LemeshowS, SaulnierF. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA, 1993; 270(24):2957–2963.
25.
VincentJL, MorenoR, TakalaJ, WillattsS, De MendoncaA, BruiningH, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med, 1996; 22(7):707–710.
26.
SinhaP, CalfeeCS, BeitlerJR, SoniN, HoK, MatthayMA, KalletRH. Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome. Am J Respir Crit Care Med, 2019; 199(3):333–341.
27.
Siggaard-AndersenO. An acid-base chart for arterial blood with normal and pathophysiological reference areas. Scand J Clin Lab Invest, 1971; 27(3):239–245.
28.
TiruvoipatiR, PilcherD, BuscherH, BothaJ, BaileyM. Effects of hypercapnia and hypercapnic acidosis on hospital mortality in mechanically ventilated patients. Crit Care Med, 2017; 45(7):e649–e656.
29.
BellaniG, LaffeyJG, PhamT, FanE, BrochardL, EstebanA, et al. LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA, 2016; 315(8):788–800.
30.
SiegelER, ZhuoH, SinhaP, PapolosAI, NiSA, VesselK, et al. Ventilatory ratio is a valuable prognostic indicator in an observational cohort of patients with ARDS. Respir Care, 2022; 67(9):1075–1081.
31.
KalletRH, ZhuoH, HoK, LipnickMS, GomezA, MatthayMA. Lung injury etiology and other factors influencing the relationship between dead-space fraction and mortality in ARDS. Respir Care, 2017; 62(10):1241–1248.
32.
MarongiuI, SpinelliE, ScottiE, MazzuccoA, WangY-M, ManessoL, et al. Addition of 5% CO2 to inspiratory gas prevents lung injury in an experimental model of pulmonary artery ligation. Am J Respir Crit Care Med, 2021; 204(8):933–942.
33.
WangN, GatesKL, TrejoH, FavoretoS, SchleimerRP, SznajderJI, et al. Elevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophage. FASEB J, 2010; 24(7):2178–2190.
34.
VadászI, DadaLA, BrivaA, TrejoHE, WelchLC, ChenJ, et al. AMP-activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na,K-ATPase endocytosis. J Clin Invest, 2008; 118(2):752–762.
35.
BrivaA, VadászI, LecuonaE, WelchLC, ChenJ, DadaLA, et al. High CO2 levels impair alveolar epithelial function independently of pH. PloS One, 2007; 2(11):e1238.
36.
LangJDJr, ChumleyP, EiserichJP, EstevezA, BambergT, AdhamiA, et al. Hypercapnia induces injury to alveolar epithelial cells via a nitric oxide-dependent pathway. Am J Physiol Lung Cell Mol Physiol, 2000; 279(5):L994–L1002.
37.
O'TooleD, HassettP, ContrerasM, HigginsBD, McKeownSTW, McAuleyDF, et al. Hypercapnic acidosis attenuates pulmonary epithelial wound repair by an NF-kappaB dependent mechanism. Thorax, 2009; 64(11):976–982.
38.
DoerrCH, GajicO, BerriosJC, CaplesS, AbdelM, LympJF, HubmayrRD. Hypercapnic acidosis impairs plasma membrane wound resealing in ventilator-injured lungs. Am J Respir Crit Care Med, 2005; 171(12):1371–1377.
39.
ShigemuraM, LecuonaE, SznajderJI. Effects of hypercapnia on the lung. J Physiol, 2017; 595(8):2431–2437.
40.
O'CroininDF, NicholAD, HopkinsN, BoylanJ, O'BrienS, O'ConnorC, et al. Sustained hypercapnic acidosis during pulmonary infection increases bacterial load and worsens lung injury. Crit Care Med, 2008; 36(7):2128–2135.
41.
McNameeJJ, GilliesMA, BarrettNA, PerkinsGD, TunnicliffeW, YoungD, et al. REST Investigators. Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. JAMA, 2021; 326(11):1013–1023.
